Premium
Alternative interferons and immunomodulators in the treatment of hepatitis C
Author(s) -
Alao Hawwa,
Jake Liang T.
Publication year - 2014
Publication title -
liver international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.873
H-Index - 110
eISSN - 1478-3231
pISSN - 1478-3223
DOI - 10.1111/liv.12402
Subject(s) - medicine , interferon , immunology , hepatitis , hepatitis c , intensive care medicine
Interferon‐α ( IFN‐ α) has been the mainstay of therapy for hepatitis C and is currently being combined with other drugs to improve the response rate. Newer therapeutic regimens are being developed to spare the use of IFN because of the important side effects associated with IFN ‐based therapy. However, there may still be a need for the use of IFN in certain populations. In addition, agents that mimic the actions of IFN but with fewer side effects may still be of major value. This review focuses on the development of alternative and new forms of IFN s and other immunomodulatory agents that may supplant IFN ‐α in combination therapy for hepatitis C.